Nootropic Agents

• 

  Subject Areas on Research

  • A randomized exploratory trial of an α-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia. 
  • A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer's disease in outpatients treated with donepezil. 
  • Age-related declines in exploratory behavior and markers of hippocampal plasticity are attenuated by prenatal choline supplementation in rats. 
  • An examination of Alzheimer's disease case definitions using Medicare claims and survey data. 
  • Attention-modulating effects of cognitive enhancers. 
  • Australian university students' attitudes towards the use of prescription stimulants as cognitive enhancers: perceived patterns of use, efficacy and safety. 
  • Begging important questions about cognitive enhancement, again. 
  • CAP--advancing the evaluation of preclinical Alzheimer disease treatments. 
  • Characterization of the facilitative effects of perinatal choline supplementation on timing and temporal memory. 
  • Chemical knockout of pantothenate kinase reveals the metabolic and genetic program responsible for hepatic coenzyme A homeostasis. 
  • Clinical correlates of cognitive decline in vascular dementia. 
  • Clinical trials in children with Down syndrome: issues from a cognitive research perspective. 
  • Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far? 
  • Cognitive enhancers for the treatment of ADHD. 
  • Cognitive impairment as a target for pharmacological treatment in schizophrenia. 
  • Combination pharmacotherapy: a mixture of small doses of naltrexone, fluoxetine, and a thyrotropin-releasing hormone analogue reduces alcohol intake in three strains of alcohol-preferring rats. 
  • Comparative cardiovascular safety of dementia medications: a cross-national study. 
  • Donepezil effects on language in children with Down syndrome: results of the first 22-week pilot clinical trial. 
  • Donepezil for cognitive decline following coronary artery bypass surgery: a pilot randomized controlled trial. 
  • EU/US/CTAD Task Force: Lessons Learned from Recent and Current Alzheimer's Prevention Trials. 
  • Effect of R3487/MEM3454, a novel nicotinic alpha7 receptor partial agonist and 5-HT3 antagonist on sustained attention in rats. 
  • Effects of donepezil on cortical activation in mild cognitive impairment: a pilot double-blind placebo-controlled trial using functional MR imaging. 
  • Effects of prenatal nicotine exposure on primate brain development and attempted amelioration with supplemental choline or vitamin C: neurotransmitter receptors, cell signaling and cell development biomarkers in fetal brain regions of rhesus monkeys. 
  • Effects of tobacco smoke constituents, anabasine and anatabine, on memory and attention in female rats. 
  • Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study. 
  • Guidelines for the use of tacrine in Alzheimer's disease: clinical application and effectiveness. Johns Hopkins Dementia Research Clinic. 
  • H2 histamine receptor blockade in the treatment of Alzheimer disease: a randomized, double-blind, placebo-controlled trial of nizatidine. 
  • Impact of APOE in mild cognitive impairment. 
  • Involvement of dopamine D2 receptors in the suppressive effect of the thyrotropin-releasing hormone analog TA-0910 on alcohol intake in alcohol-preferring rats. 
  • Large-Scale Cognitive GWAS Meta-Analysis Reveals Tissue-Specific Neural Expression and Potential Nootropic Drug Targets. 
  • Long-term citicoline (cytidine diphosphate choline) use in patients with vascular dementia: neuroimaging and neuropsychological outcomes. 
  • Methods for delivering and evaluating the efficacy of cognitive enhancement. 
  • Multi-Trait Analysis of GWAS and Biological Insights Into Cognition: A Response to Hill (2018). 
  • N-aryl piperazine metabotropic glutamate receptor 5 positive allosteric modulators possess efficacy in preclinical models of NMDA hypofunction and cognitive enhancement. 
  • Neuroimaging correlates of dementia rating scale performance at baseline and 12-month follow-up among patients with vascular dementia. 
  • Neuroinflammation in Alzheimer's disease. 
  • Oscillatory bands, neuronal synchrony and hippocampal function: implications of the effects of prenatal choline supplementation for sleep-dependent memory consolidation. 
  • Pain and palliative care pharmacotherapy literature summaries and analyses. 
  • Poststroke pharmacotherapy: another ictus. 
  • Prenatal choline exposure alters hippocampal responsiveness to cholinergic stimulation in adulthood. 
  • Prenatal choline supplementation alters the timing, emotion, and memory performance (TEMP) of adult male and female rats as indexed by differential reinforcement of low-rate schedule behavior. 
  • Prenatal choline supplementation increases NGF levels in the hippocampus and frontal cortex of young and adult rats. 
  • Prenatal choline supplementation increases sensitivity to contextual processing of temporal information. 
  • Prenatal dietary choline availability alters postnatal neurotoxic vulnerability in the adult rat. 
  • Prenatal-choline supplementation differentially modulates timing of auditory and visual stimuli in aged rats. 
  • Progressive morphometric and cognitive changes in vascular dementia. 
  • Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia. 
  • Report on ISCTM Consensus Meeting on Clinical Assessment of Response to Treatment of Cognitive Impairment in Schizophrenia. 
  • Reversal of chlorpyrifos neurobehavioral teratogenicity in mice by nicotine administration and neural stem cell transplantation. 
  • Severe parkinsonian symptom development on combination treatment with tacrine and haloperidol. 
  • Spatial memory and hippocampal plasticity are differentially sensitive to the availability of choline in adulthood as a function of choline supply in utero. 
  • The Alzheimer's Disease Assessment Scale: evaluation of psychometric properties and patterns of cognitive decline in multicenter clinical trials of mild to moderate Alzheimer's disease. 
  • The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later? 
  • The discovery and early validation of novel plasma biomarkers in mild-to-moderate Alzheimer's disease patients responding to treatment with rosiglitazone. 
  • The efficacy, safety, and tolerability of donepezil for the treatment of young adults with Down syndrome. 
  • Therapeutic and prophylactic utility of the memory-enhancing drug donepezil hydrochloride on cognition of patients undergoing electroconvulsive therapy: a randomized controlled trial. 
  • Thyrotropin releasing hormone analog TA-0910 suppresses alcohol intake in alcohol drinking African green monkeys. 
  • Thyrotropin-releasing hormone analog TA-0910 reduces voluntary alcohol intake of P rats subchronically in a limited scheduled access paradigm. 
  • Treating cognitive deficits in multiple sclerosis: are we there yet? 
  • [Effect of aspartic acid derivatives, N-acetyl-aspartate and its phosphonic analog PIR-87-6-0, on dopamine release from the rat striatum during perfusion in vitro]. 
  • [The effect of a low dose of piracetam on the activity of the dopaminergic system in the rat striatum]. 
• 

  Keywords of People

  • Bradford, Daniel William, Associate Professor of Psychiatry and Behavioral Sciences, Psychiatry & Behavioral Sciences, Social and Community Psychiatry
  • Charles, Hal Cecil, Associate Professor of Radiology, Radiology